We would like to share some of the latest developments in the industry and provide an outlook of some of our key activities. If you would like to receive this update straight to your inbox, please feel free to sign up to our monthly newsletter.
Industry News
Sustainability is becoming increasingly important for biomanufacfuring. This recent paper in New Biotechnology journal, ScienceDirect, discusses strategies to ensure resiliency and investigates metrics, such as Process Mass Intensity (PMI), to identify areas of improvement. The authors have discovered that the PMI for monoclonal antibodies varies widely depending on titer and chromatography during purification.
News at Just - Evotec Biologics
DCAT Sustainability Summit
At this year’s DCAT Sustainability Summit we showcased how our continuous manufacturing platform can improve the sustainability of biologics production. Here are some key takeaways.
Our platform allows for:
- 50% less process water
- 65% less plastic waste
- 73% lower CO2 emissions
Achieving Continuous Manufacturing Through Equipment Design
Purification Tangential Flow Filtration System
We’re thrilled to share insights from the forefront of biomanufacturing innovation. Expertise in single-use equipment design is critical to our success. Download the highlights of Andrea Isby’s insightful presentation from Repligen’s DSP Workshop in Estonia, held on May 23rd, 2024.
Accelerating Continuous Biomanufacturing Process Design
We attended and presented at the recent Recovery of Biological Products Conference in Oregon. Andrew Wagner presented a poster on how we automate the visualization of high-throughput datasets for downstream process development.
Upcoming Webinar
Conversion of Fed-Batch to Continuous Bioprocess
Biopharma companies increasingly recognize the need to switch existing fed-batch processes to Integrated Continuous Bioprocess (ICB) platforms as an alternative to scale-up or scale-out approaches for increasing the output of antibody drug substance. Furthermore, ICB facilities allow greater flexibility and better process economics, helping drive down the cost for overall therapeutic protein production. Just - Evotec Biologics is collaborating with partners to seamlessly make this transition.
Brian Follstad
Director Process Sciences
In this webinar, Dr. Brian Follstad will present a case study in which we performed the rapid conversion of an Intensified Fed-Batch monoclonal antibody process to an Integrated Continuous Bioprocess in less than six months from project start to cGMP batch completion resulting in a 5-fold increase in product mass from the bioreactor while minimizing risks from product quality changes.
Recent Press Releases
Just - Evotec Biologics Completes cGMP Clinical Manufacturing for FibroGen's Phase I Study for Manufacturing Optimization Program
cGMP clinical materials manufactured for FibroGen have been cleared for clinical use by the United States Food and Drug Administration (“FDA”) as part of FibroGen’s Investigational New Drug (“IND”) filing.
Just - Evotec Biologics Selected by U.S. Department of Defense for Manufacturing Optimization Program
Just – Evotec Biologics was selected by the DOD to develop an accelerated monoclonal antibody development and manufacturing solution for the DOD’s Manufacturing Optimization Program. The multi-year program award supports the U.S. Government’s effort to enhance its rapid response capabilities for biologics medical countermeasures - MCMs.
